BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 215 filers reported holding BRIDGEBIO PHARMA INC in Q3 2021. The put-call ratio across all filers is 1.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $243,026 | -77.7% | 9,216 | -93.6% | 0.01% | -80.6% |
| Q4 2022 | $1,090,171 | -28.8% | 143,067 | -7.2% | 0.03% | -42.6% |
| Q3 2022 | $1,532,000 | +168.3% | 154,090 | +145.1% | 0.05% | +107.7% |
| Q2 2022 | $571,000 | -58.3% | 62,880 | +115.3% | 0.03% | -76.1% |
| Q3 2021 | $1,369,000 | +242.2% | 29,204 | +344.8% | 0.11% | +220.6% |
| Q2 2021 | $400,000 | +33.3% | 6,566 | +34.8% | 0.03% | +21.4% |
| Q1 2021 | $300,000 | -38.0% | 4,870 | -62.3% | 0.03% | -9.7% |
| Q3 2020 | $484,000 | -31.6% | 12,906 | -40.6% | 0.03% | -36.7% |
| Q2 2020 | $708,000 | – | 21,718 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |